Glenmark Pharmaceuticals Limited — Investor Meet, 16-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Glenmark's Investor Day 2025 outlined 'Glenmark 3.0', emphasizing sustained value creation through an innovation-led, global strategy. Key focus areas are Dermatology, Respiratory, and Oncology. The Ichnos Glenmark Innovation (IGI) unit is set to become self-sustaining following the US$700 million upfront AbbVie deal, which will boost Glenmark's consolidated EBITDA to 23% from FY26 and add US$70 million annually to cash. Mid-term financial goals include 12-14% revenue CAGR, 7-7.5% R&D spend, and ROCE/ROE exceeding 20%. The company appears optimistic about its diversified approach and disciplined financial management.